Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma

Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma

Abstract Background Anaplastic thyroid carcinoma (ATC) is a rare but deadly form of thyroid cancer. Kinase inhibitors kinase inhibitors have shown clinical efficacy in the management of ATC, however, eventually these tumors acquire resistance to KI and patients succumb to their disease. Salvage ther...

Full description

Bibliographic Details
Main Authors: Priyanka C. Iyer, Ramona Dadu, Maria Gule-Monroe, Naifa L. Busaidy, Renata Ferrarotto, Mouhammed Amir Habra, Mark Zafereo, Michelle D. Williams, G. Brandon Gunn, Horiana Grosu, Heath D. Skinner, Erich M. Sturgis, Neil Gross, Maria E. Cabanillas
Format: Article
Language:English
Published: BMJ Publishing Group 2018-07-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Anaplastic thyroid cancer
Immunotherapy
Salvage
Thyroid cancer
Lenvatinib
Dabrafenib
Online Access:http://link.springer.com/article/10.1186/s40425-018-0378-y

Internet

http://link.springer.com/article/10.1186/s40425-018-0378-y

Similar Items